Literature DB >> 28551069

Gene expression of sphingolipid metabolism pathways is altered in hidradenitis suppurativa.

Mohammed Dany1, Dirk Elston2.   

Abstract

BACKGROUND: Hidradenitis suppurativa (HS) is a debilitating skin disease characterized by painful recurrent nodules and abscesses caused by chronic inflammation. Early events in the development of HS are believed to occur in the folliculopilosebaceous unit; however, the signaling pathways behind this mechanism are unknown. Sphingolipids, such as ceramide, are essential components of the skin and appendages and have important structural and signaling roles.
OBJECTIVE: We sought to explore whether the gene expression of enzymes involved in sphingolipid metabolic pathways is altered in HS.
METHODS: A microarray data set including 30 samples was used to compare the expression of sphingolipid-related enzymes in inflammatory skin lesions from HS patients (n = 17) with the expression in clinically healthy skin tissue (n = 13). Differential expression of sphingolipid metabolism-related genes was analyzed using Gene Expression Omnibus 2R.
RESULTS: HS lesional skin samples have significantly decreased expression of enzymes generating ceramide and sphingomyelin, increased expression of enzymes catabolizing ceramide to sphingosine, and increased expression of enzymes converting ceramide to galactosylceramide and gangliosides. LIMITATIONS: Limitations of this study include assessing the expression of sphingolipid-related enzymes without assessing the levels of the related sphingolipids.
CONCLUSION: Our study suggests that sphingolipid metabolism is altered in HS lesional skin compared with normal skin.
Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ceramide; hexosylceramide; hidradenitis suppurativa; lipid metabolism; perilipin; sphingolipids

Mesh:

Substances:

Year:  2017        PMID: 28551069     DOI: 10.1016/j.jaad.2017.03.016

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

Review 1.  The role of dihydrosphingolipids in disease.

Authors:  Ruth R Magaye; Feby Savira; Yue Hua; Darren J Kelly; Christopher Reid; Bernard Flynn; Danny Liew; Bing H Wang
Journal:  Cell Mol Life Sci       Date:  2018-12-06       Impact factor: 9.261

2.  Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature.

Authors:  Lauren K Hoffman; Lewis E Tomalin; Gregory Schultz; Michael D Howell; Niroshana Anandasabapathy; Afsaneh Alavi; Mayte Suárez-Fariñas; Michelle A Lowes
Journal:  PLoS One       Date:  2018-09-28       Impact factor: 3.240

3.  T helper (Th)17 radiation-induced hidradenitis suppurativa.

Authors:  Mohammed Dany; Tina Rendini; William Levis
Journal:  JAAD Case Rep       Date:  2018-04-30

4.  Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model.

Authors:  Allard R J V Vossen; Hessel H van der Zee; Errol P Prens
Journal:  Front Immunol       Date:  2018-12-14       Impact factor: 7.561

Review 5.  An Integrated Approach to Unravel Hidradenitis Suppurativa Etiopathogenesis.

Authors:  Paola M Tricarico; Michele Boniotto; Giovanni Genovese; Christos C Zouboulis; Angelo V Marzano; Sergio Crovella
Journal:  Front Immunol       Date:  2019-04-25       Impact factor: 7.561

6.  Atherogenic index of plasma is associated with the severity of Hidradenitis Suppurativa: a case-control study.

Authors:  José L Hernández; Cristina Baldeón; Ana E López-Sundh; J Gonzalo Ocejo-Vinyals; Ricardo Blanco; Marcos A González-López
Journal:  Lipids Health Dis       Date:  2020-08-29       Impact factor: 3.876

Review 7.  Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing-A Molecular Meta-Analysis.

Authors:  Viktor A Zouboulis; Konstantin C Zouboulis; Christos C Zouboulis
Journal:  Pharmaceutics       Date:  2021-12-26       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.